The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
Dea Belazi
Advertisement
Dea Belazi is President and CEO of AscellaHealth.
Articles by Dea Belazi
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma
2
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX
3
In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore
4
FDA Continues to Expand National Priority Voucher Program
5
